pertuzumab,pembrolizumab,dostarlimab,talazoparib,durvalumab,trastuzumab,olaparib,paclitaxel,neratinib,cemiplimab,ganetespib,irinotecan,tucatinib
gsk,bms,amgen,astrazeneca,daiichi sankyo,merck,roche
['i-spy', 'breast', 'bcsm']
i-spy2: pcr by molecular subtype for hr+/her2- breast cancer. higher pcr rates in mammaprint high2, blueprint basal, and rps immune+ signature. future randomization planned based on rps subtype. of #asco22 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.